Industry N Nature Medicine
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry N Nature Medicine
Industry
TechCrunch Biotech and Health
Intero Biosystems beat out 199 other Startup Battlefield companies to take home the $100,000 grand prize at TechCrunch Disrupt 2026.
Regulatory
BioCentury
BIOCENTURY | REGULATIONFDA SIGNALS INTENT TO IMPROVE CONSISTENCY, SEEK EXTERNAL ADVICE ON RARE DISEASE THERAPIES‘Catastrophically broken’ agency could struggle to implement reforms, former Acting Commissioner Woodcock warns
Industry
BioCentury
BIOCENTURY | DEALSROCHE TURNS TO CHINA’S RONA FOR ALK7-SIRNA FOR SELECTIVE FAT LOSSChina biotechs fuel a growing RNAi pipeline silencing ALK7 in adipocytes
Manufacturing B BioProcess International
An expert discusses outsourcing in the rapidly evolving radiopharmaceutical space.
Industry
BioCentury
BIOCENTURY | DATA BYTECHINA’S RNAI PIPELINE DRIVES DEALMAKING WITH THE WESTCardiometabolic programs lead the dealmaking as China’s developers push delivery beyond the liver
Research
GEN
5,812 protein groups were quantified in postmenopausal ovaries, uncovering molecular shifts associated with inflammation, immunity, and extracellular matrix remodeling. The post Proteomics Reveals Ovarian Remodeling Decades After Menopause appeared first on GEN - Genetic Engineer…
Industry
BioCentury
BIOCENTURY | MANAGEMENT TRACKSSTOFFELS, KREMER LAND AT ARMED CELL, TAKE RIGHTS TO EX-GALAPAGOS PROGRAMSPlus: Changes at iOnctura and Actinium
Funding
BioCentury
BIOCENTURY | FINANCEOMASS’ $310M ROUND AMONG U.K.’S LARGEST EVER FOR A BIOTECH: VENTURE REPORTPlus: OrbiMed’s $3B pair of funds includes cash for Asia; rounds for Souffle and Altay; and more
Industry
C&EN Pharmaceuticals
Biotechs in the US and Europe face challenges, but as a recent panel discussion made clear, the competition offers global benefits
Clinical
Fierce Biotech
Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions scox Thu, 10/15/2026 - 16:06
Industry
STAT Biotech
Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.
Software S SecureBio
Beyond our own biosurveillance work, we at SecureBio Detection consider it part of our mission to advance the science of infectious disease monitoring as a whole.
Manufacturing B BioPharm International
Emily Heffernan of Arcadis explains how facility scale, equipment, containment, and quality testing differ across ex vivo cell therapy, viral vector, and mRNA-LNP manufacturing.
Funding
MedCity News
Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline of internally discovered and wholly owned cancer drugs. Iambic also has R&D alliances with companies such as Bayer and AbbVie. The post AI Biotech Iambi…
Regulatory B BioPharm International
FDA expands Anktiva’s bladder cancer indication, Alvotech and Advanz submit a proposed Eylea 8 mg biosimilar in Europe, and Lilly reports new remission data for Omvoh in inflammatory bowel disease.
Industry
Fierce Biotech
Accelerate the timeline from gene to lead cline with new GS Ori-Go® vector Drug developers face tremendous pressure to increase efficiency and productivity, and reduce development timelines. At Lonza, focused innovation efforts aimed at addressing these demands have yielded a num…
Clinical A Applied Clinical Trials
Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the desi…
Industry
GEN
Hundreds of newly identified microexons seem to matter for autism and other neurological conditions, according to a Nature study. A machine learning model of their regulatory code also pinpoints variants predicted to disrupt their splicing in autistic individuals. The post Newly…
Software P Pharmaceutical Commerce
Zoomlogi’s Henry Ames says exception handling still hinges on experienced staff, and AI agents could gather and document details for their judgment calls.
Clinical
Fierce Pharma
The Next Chapter for AI in Clinical Trials lbarrick Thu, 10/15/2026 - 13:31
Research
Inside Precision Medicine
Candida auris can make multiple copies of its entire genome, including mutations in key genes, to increase its chances to resist treatment. The post <i>Candida auris</i> Copies Whole Genome to Evade Antifungal Treatment appeared first on Inside Precision Medicine.
Industry
Inside Precision Medicine
Targeting a vital cellular signaling pathway that contributes to bone loss together with supplementation of a vitamin B derivative could help prevent osteoporosis. The post Key Molecular Driver Implicated in Osteoporosis appeared first on Inside Precision Medicine.
Industry
GEN
Study linked the APOE4 gene with suppression of Wnt signaling in the oligodendrocyte cells that provide neurons with their fatty myelin insulation, and also demonstrated a potential approach to preventing disruption of myelination. The post How Alzheimer’s Risk Gene <i>APOE…
Industry
C&EN Pharmaceuticals
Local activation could deliver targeted therapy with fewer side effects
Clinical
Fierce Pharma
Why Are 53% of Phase 2 and 3 Trials Delayed? A Redesign Is Overdue jpiatt Thu, 10/15/2026 - 12:32
Industry
Fierce Biotech
Cracking complexity: Leveraging lessons learned for future bispecific development The biologics pipeline is becoming increasingly complex as next-generation antibody formats, including bispecific antibodies (BsAbs), move rapidly toward the clinic. For early-stage biotech teams, t…
Software B Biotech Currents
Assigning a 62.5% overall probability the company will meet 2 catalysts
Research
BioPharma Dive
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
Industry
Drug Delivery Business
MiniMed (Nasdaq: MMED) is celebrating its first day as an independent diabetes tech company, with the full completion of its spinoff from the Medtronic mothership. This week Medtronic reported the final results of its exchange offer for MiniMed stock, where it divested all of its…
Research
MedTech Dive
The results come as Dexcom is awaiting a decision from the Centers for Medicare and Medicaid Services to expand Medicare coverage of the devices for people with Type 2 diabetes.
Industry
GEN
Illumina is bringing its software, AI, and data offerings together in the new BioInsight platform, designed to help scientists analyze genomic and multiomic datasets. It will be showcased at ASHG in Montreal. The post Illumina Combines Multiomics Informatics Applications in New B…
Industry
STAT Biotech
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…
Clinical
STAT Biotech
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
Regulatory
BioPharma Dive
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
Industry
Clinical Trials Arena
Verastem is advancing the KRAS inhibitor into later stage studies following the data readout. The post Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC appeared first on Clinical Trials Arena.
Software P Pharmaceutical Executive
AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
Industry
MedTech Dive
Labcorp will pick up specialty testing in women’s health as well as a blood test that assesses the likelihood of finding aggressive prostate cancer before a biopsy decision.
Industry B BioPharm International
AVT29, a proposed aflibercept biosimilar to Eylea 8 mg, could extend retinal disease treatment intervals to 16 weeks, versus 8 weeks today.